Literature DB >> 21737333

Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy.

J Crouzet1, J P Lavigne, J L Richard, A Sotto.   

Abstract

Controlled clinical trials are essential tools for evaluating the efficacy of antibiotic treatment against infection, but the results of such trials critically depend on sensitive, reproducible, and feasible outcome measures. We reviewed randomized controlled trials on the antibiotic treatment of diabetic foot infection published between 1999 and 2009 in terms of quality and endpoints. Discrepancies in study design, inclusion criteria, statistical methodology, and the varying definitions of both clinical and microbiological endpoints between the published studies, make it difficult to compare them, as well as to determine which regimen may be the most appropriate for patients with diabetic foot infection.
Copyright © 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737333     DOI: 10.1016/j.ijid.2011.05.003

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

1.  Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days.

Authors:  Karim Gariani; Jean-Christophe Richard; Benjamin Kressmann; François R Jornayvaz; Jacques Philippe; Benjamin A Lipsky; Ilker Uçkay
Journal:  Ann Surg       Date:  2021-09-15       Impact factor: 13.787

2.  From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers.

Authors:  C Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

3.  Cytosolic and Calcium-Independent Phospholipases A2 Activation and Prostaglandins E2 Are Associated with Escherichia coli-Induced Reduction of Insulin Secretion in INS-1E Cells.

Authors:  Nunzia Caporarello; Mario Salmeri; Marina Scalia; Carla Motta; Cristina Parrino; Lucia Frittitta; Melania Olivieri; Martina Cristaldi; Roberto Avola; Vincenzo Bramanti; Maria Antonietta Toscano; Carmelina Daniela Anfuso; Gabriella Lupo
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

4.  Assessing the Effect of Piperacillin/Tazobactam on Hematological Parameters in Patients Admitted with Moderate or Severe Foot Infections.

Authors:  Will Fry; Sean McCafferty; Catherine Gooday; Ian Nunney; Ketan K Dhatariya
Journal:  Diabetes Ther       Date:  2018-01-04       Impact factor: 2.945

5.  The appropriate management algorithm for diabetic foot: A single-center retrospective study over 12 years.

Authors:  Jung Woo Chang; Woong Heo; Matthew Seung Suk Choi; Jang Hyun Lee
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

6.  Is there concordance between bone and tendon cultures in patients with foot tissue loss?

Authors:  Vanessa Prado Dos Santos; Carlos Alberto Silveira Alves; André Brito Queiroz; Maria Goreth Matos de Andrade Barberino; Ronald José Ribeiro Fidelis; Cícero Fidelis; José Siqueira de Araújo
Journal:  J Vasc Bras       Date:  2019-11-08

7.  Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.

Authors:  N C Schaper; M Dryden; P Kujath; D Nathwani; P Arvis; P Reimnitz; J Alder; I C Gyssens
Journal:  Infection       Date:  2012-11-23       Impact factor: 3.553

Review 8.  Inpatient management of diabetic foot disorders: a clinical guide.

Authors:  Dane K Wukich; David G Armstrong; Christopher E Attinger; Andrew J M Boulton; Patrick R Burns; Robert G Frykberg; Richard Hellman; Paul J Kim; Benjamin A Lipsky; James C Pile; Michael S Pinzur; Linda Siminerio
Journal:  Diabetes Care       Date:  2013-09       Impact factor: 19.112

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.